Arax Advisory Partners’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
AI
Arax Advisory Partners's CRL Position: Q2 2026 in Review
Arax Advisory Partners increased its Charles River Laboratories (CRL) stake by 214% in Q2 2026, buying an estimated $275K and bringing the position to 2,264 shares worth $513K. The position accounts for ﹤0.01% of the portfolio, ranked #1620.
Arax Advisory Partners first reported a position in CRL in Q2 2022 and has held it in 17 quarters since. The position peaked at $850K in Q3 2025. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Arax Advisory Partners held 2,264 shares of Charles River Laboratories worth $513K as of Q2 2026.
- Arax Advisory Partners bought 1,543 Charles River Laboratories shares in Q2 2026, an estimated $275K.
- Charles River Laboratories made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1620 holding.
- Arax Advisory Partners first reported a position in Charles River Laboratories in Q2 2022 and has held it in 17 quarters since.
- Arax Advisory Partners's Charles River Laboratories position peaked at $850K in Q3 2025.
- 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.